Last July, Nasdaq-listed MEI Pharma announced its move for a crypto reserve and chose Litecoin (LTC) for it.
Following this announcement, MEI Pharma implemented its reserve strategy and purchased $100 million worth of LTC.
According to the official announcement, MEI Pharma made its first LTC purchase and launched a $100 million corporate treasury strategy with Litecoin founder Charlie Lee and GSR acting as advisors.
MEI Pharma announced today that it has purchased 929,548 Litecoin at an average price of $107.58, successfully launching a major corporate treasury strategy that will see its LTC treasury valued at approximately $110.4 million as of August 4, 2025.
MEI Pharma has become the first US-listed public company to adopt Litecoin as its primary reserve asset.
“Litecoin has long been the symbol of a robust, scalable, and decentralized currency. By launching this strategy, MEI is taking a clear, institutional step that recognizes Litecoin’s role as both a reserve asset and an integral part of global financial systems,” said Charlie Lee.
Litecoin has seen a massive surge compared to other altcoins in the last 24 hours, rising 7% to $123.8.
*This is not investment advice.
Source: https://en.bitcoinsistemi.com/nasdaq-listed-us-company-enters-this-altcoin-with-loads-becoming-the-first-company/